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Abstract The plant phytoalexin resveratrol was previ-
ously demonstrated to inhibit the differentiation and bone
resorbing activity of osteoclasts, to promote the formation
of osteoblasts from mesenchymal precursors in cultures,
and inhibit myeloma cell proliferation, when used at high
concentrations. In the current study, we screened five
structurally modified resveratrol analogues for their ability
to modify the differentiation of osteoclasts and osteoblasts
and proliferation of myeloma cells. Compared to resvera-
trol, analogues showed an up to 5,000-fold increased
potency to inhibit osteoclast differentiation. To a lesser
extent, resveratrol analogues also promoted osteoblast
maturation. However, they did not antagonize the prolif-
eration of myeloma cells. The potency of the best-per-
forming candidate in vitro was tested in vivo in an
ovariectomy-induced model of osteoporosis, but an effect
on bone loss could not be detected. Based on their powerful
antiresorptive activity in vitro, resveratrol analogues might
be attractive modulators of bone remodeling. However,
further studies are required to establish their efficacy in
vivo.
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Resveratrol (RSV, trans-3,5,40-hydroxystilbene) is a natu-
rally occurring phytoalexin generated in a number of plants
including grapes, mulberries, cranberries, and peanuts.
RSV has recently attracted considerable interest because of
its inhibitory activity on multiple cellular events associated
with carcinogenesis [1], and its actions on a broad cell
spectrum are well documented both in vitro and in vivo [2,
3]. These anti-cancer effects of RSV are supported by
observations in different cancer cell lines in vitro and in
animal cancer models such as breast cancer [4], skin cancer
[1], liver cancer [5], colorectal and intestinal cancers [6, 7],
lung cancers [8], and neuroblastoma [9]. The results of
preclinical studies have stimulated an interest from the
pharmaceutical industry, and several clinical studies are
ongoing in the field of cancer (colon cancer, non-Hodgkin
lymphoma, and multiple myeloma) and other areas of
clinical research.
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It was also reported that RSV may have beneficial
effects on osteoclasts (OCs) and osteoblasts (OBs) [10–13].
Noteworthy, current therapies act mainly on only one of
the remodeling processes either by inhibition of OC-med-
iated bone resorption (e.g., bisphosphonates) or by stimu-
lation of bone formation by OBs (e.g., PTH or teraparatide)
[14]. It is thus of interest that RSV has the potential both to
antagonize OCs and to promote OBs. To our knowledge,
only strontium ranelate, statins, and bortezomib share the
same potential. Furthermore, RSV and the latter two drugs
also prevent the proliferation of cancer cells in multiple
myeloma [10, 15, 16]. Multiple myeloma is an incurable
neoplasia of terminally differentiated B cells (plasma cells)
that frequently causes extensive osteolytic bone lesions
resulting in pathological fractures of bone, vertebral col-
lapse, pain and disability. The bone lesions result from a
combination of increased bone resorption and inhibition of
bone formation in the vicinity of myeloma cells [17]. It
thus appears that RSV possesses an ideal triad of proper-
ties: it suppresses OC differentiation while at the same time
stimulating the differentiation of OBs and inhibits mye-
loma cell proliferation and survival [10].
However, these effects on OCs, OBs, and myeloma
cells were seen only when RSV was used at concentra-
tions between 50 and 100 lM, while lower concentrations
seem to be ineffective. In both humans and rodents the
peak plasma levels of unmetabolized RSV are well below
this level even after a high oral dose, and its elimination
is rather rapid [18, 19]. Another problem is that the high
doses of RSV that are sufficient to obtain the desired
plasma concentrations can cause side effects such as renal
toxicity seen in rodents [20]. Furthermore, taking into
account the broad spectrum of cellular actions [reviewed
in 2, 3], RSV is a questionable option for tailored ther-
apies where a precise effect is needed. A particular con-
cern is its estrogen receptor (ER) agonistic activity [21]
associated with genotoxicity [22] and increased risk of
carcinogenesis.
Given the limited bioavailability of RSV after oral
administration, the high concentrations required to obtain
the desired effects seen in vitro, its potential toxicity, and
its complex mechanisms of actions, RSV analogues may
offer advantages over the parent compound. Structural
modifications of RSV led to analogues with improved
potency and specificity compared with the parental agent,
thereby being more tolerable and safer [23, 24]. One of the
RSV derivatives (STR501) is currently being tested in a
phase II clinical trial for the treatment of multiple myeloma
as a potent activator of Silent Information Regulator T-1,
controlling bone mass in vivo via direct regulation of OBs
and OCs [25].
In the current study, we compared the activity of a set
of RSV derivatives with the parental product. They were
designed for no affinity for the ER and higher affinity
toward the aryl hydrocarbon receptor (AhR). The modi-
fications in structure consisted of chloride substitution,
contributing to suppress ER affinity and to increase AhR
affinity [26]. ERa and ERb (jointly referred to as ‘‘ER’’ in
this article) are activated upon the ligation of estrogen.
ER functions mainly as a DNA-binding transcription
factor that regulates gene expression [27]. The engage-
ment of ER was shown to antagonize OCs and inhibit
bone resorption [28]. AhR is a transcription factor that
mediates the toxicity of ubiquitous environmental con-
taminants. AhR ligands are prevalent in tobacco smoke
[29], pesticides, and some manufactured chemicals [30];
and they may elicit toxic responses such as tumour pro-
motion [31] and immunosuppression [32]. Emerging data
indicate that AhR may also play a role in bone metabo-
lism, mainly acting on OB maturation and the modulation
of OB functions [33]. Therefore, novel RSV derivatives
with restricted activity toward ER or AhR may serve as
unique tools to determine whether the effects of the
parental compound RSV are due to one or the other
pathway.
In the present study we tested the activity of five of these
RSV analogues on OCs, OBs, and myeloma cells in cul-
tures. The best candidate was selected for in vivo testing,
using ovariectomized (OVX) rats as a model of estrogen-
induced bone loss.
Materials and Methods
RSV Analogues
RSV derivatives displaying different affinity toward ER
and AhR are shown in Table 1 and further described in de
Medina et al. [26]. Additional PDM02, PDM10, and
PDM11 stocks were supplied from Cayman Chemical
(Tallinn, Estonia) and solubilized in sterile 99% ethanol.
For the animal study PDM02 was dissolved in DMSO.
Cell Cultures
Myeloma cell lines U266 and OPM-2 were obtained from
DSMZ (Braunschweig, Germany) and cultured at 37C in
RPMI 1640 medium (GIBCO, Taastrup, Denmark) sup-
plemented with 10% FCS. Media were replaced every
other day. Primary myeloma cells were isolated from bone
marrow aspirates from myeloma patients as a part of the
diagnostic procedure after informed consent (ethical com-
mittee approval S-20070019). Myeloma cells were sorted
immunomagnetically using MACS anti-CD138 magnetic
beads (Miltenyi Biotech, Bergisch Gladbach, Germany) as
recommended by the manufacturer. The purity of isolated
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myeloma cells varied from 70 to 90% as determined by
flow cytometric analysis with anti-CD138 antibody (Bec-
ton Dickinson, Heidelberg, Germany).
To monitor cell viability upon treatment with RSV
analogues, myeloma cells were seeded in flat-bottomed 96-
well plates at 5 9 104 cells/well in 200 lL of RPMI 1640
medium in the presence or absence of 10% FCS and
increasing concentrations of RSV analogues. The meta-
bolic activity of the cells as a surrogate marker of cell
viability was measured with the XTT Cell Proliferation Kit
(Roche, Hvidovre, Denmark) according to the manufac-
turer’s recommendations. Apoptotic cells were labeled
with Annexin V and propidium iodide (Annexin-V Apop-
tosis Detection Kit, BD Pharmingen, Brondby, Denmark)
and analyzed on a flow cytometer (Becton Dickinson).
Human OC precursors were prepared from whole blood
obtained from healthy donors at Vejle Hospital after writ-
ten informed consent (ethical committee approval
S-20070019). Isolation of CD14? monocytes, OC differ-
entiation, and monitoring of both tartrate-resistant acid
phosphatase (TRAP) activity and number of TRAP-posi-
tive multinucleated cells were performed as described
previously [10]. Cell viability upon treatment with RSV
analogues was determined using Cell Titer Blue Viability
Assay (Promega, Nacka, Sweden) according to the manu-
facturer’s recommendations.
For OB differentiation, we used the well-characterized
human bone marrow mesenchymal stem cell line hMSC-
TERT (hMSC), which stably expresses human telomerase
reverse transcriptase gene (TERT) [34, 35]. hMSC cells
were grown in phenol red-free MEM (GIBCO) supple-
mented with 10% FCS. At 60–70% cell confluence, media
were replaced with OB differentiating medium (ODM)
containing 10-9 mol/L 1,25(OH)2D3, 50 lg/mL L-ascorbic
acid, 10-9 mol/L dexamethasone, and 10-3 mol/L b-
glycerophosphate (all from Sigma, Brondby, Denmark) and
increasing concentrations of RSV analogues. hMSC-TERT
cells were then cultured at 37C up to 5 days, with media
replacement every other day. Cell viability upon treatment
with RSV analogues was assessed using the Cell Titer
Blue Viability Assay (Promega) as recommended by the
manufacturer.
Bone Resorption Assays
For bone resorption assays [10], OC precursors were cul-
tured for 2 days with rhM-CSF (25 ng/mL) and thereafter
differentiated for 7 days with rhM-CSF and rhRANKL
(25 ng/mL each; R&D Systems, Abingdon, UK). Cells
were harvested by trypsin treatment and seeded on bone
slices (6 mm in diameter; IDS, Herlev, Denmark) at a
density of 105 cells in 200 lL of a-MEM supplemented
with 10% FCS, rhM-CSF, rhRANKL (25 ng/mL each), and
increasing concentrations of RSV analogues. OCs were
cultured at 37C for up to 3 days. At the end of the
experiment, cells were scraped off in water using a cotton
stick, and resorption pits were visualized with 0.1% tolui-
dine blue staining. The resorbed areas on bone slices were
quantified using an upright light microscope (Carl Zeiss,
Birkeroed, Denmark) equipped with a 36-point grid, and
results were presented as the total resorbed area in per-
centage of the whole bone surface.
Real-Time Quantitative PCR on OC Cultures
Relative gene expression was analyzed by TaqMan quan-
titative real-time PCR as described previously [10] using
primers and probes for cathepsin K (Hs00355885_m1),
Table 1 Receptor binding and biological activity of RSV analogues used in the study
Compound R1 R2 AhR ER
KinM Activity KinM Activity
RSV 40-OH OH 169 ± 5.2 Antagonist 785 ± 4.1 Agonist
PDM01 40-OMe OMe 7.7 ± 0.2 Antagonist 261 ± 3.2 Agonist
PDM02 40-Cl CI 1.2 ± 0.4 Antagonist [100,000
PDM06 40-CF3 CF3 2.1 ± 0.8 Antagonist [100,000
PDM10 40-CF3 CI 0.2 ± 0.4 Agonist [100,000
PDM11 40-OMe CI 1.4 ± 0.7 Antagonist [100,000
Modified from de Medina et al. [26] with permission of the author
AhR aryl hydrocarbon receptor, ER estrogen receptor
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RANK (Hs00187189_m1), c-fms (Hs00234617_m1), and
CD14 (Hs00169122_q1). NFATc1 primers and probe were
designed according to the NFATc1 Genbank accession
U08015: NFATc1-fp TGGAGAGTCCTCGCATCGA,
NFATc1-rp CATCGTGGAAAAACTGGTTATTGT, and
NFATc1-p ATAACCTCGTGCTTGGGCCTGTACCAC.
All primers and probes were purchased from Applied
Biosystems (Naerum, Denmark). Cultures of differentiat-
ing OCs treated with RSV analogues were harvested at the
time points indicated in figure legends, lysed, and subjected
to RNA isolation. Residual cell debris was removed by
centrifugation through QIA Shredder columns (Qiagen,
Hilden, Germany). Total RNA was purified from the
cleared homogenate using the RNeasy Mini kit (Qiagen).
The yield and purity of isolated RNA were verified by
spectrophotometry before reverse-transcribing into single-
stranded cDNA using the Iscript cDNA Synthesis kit (Bio-
Rad Laboratories, Copenhagen, Denmark) as recom-
mended by the manufacturer. The relative standard curve
method was used to calculate the amplification difference
for each primer set. A standard curve was made from six
points corresponding to twofold cDNA serial dilutions for
each gene. For each sample, the relative amount was cal-
culated from its respective standard curve. The quantity of
the target gene mRNA was then obtained by division of
each value by the mean relative gene expression of human
GUS (36-3026) and ABL (06-1250) used as endogenous
controls [10].
In Situ Detection of NF-jB Activation
For in situ detection of nuclear factor-jB (NF-jB) trans-
location, isolated CD14? cells were seeded in chambered
slides and treated for 2 days with 25 ng/mL rhM-CSF.
Thereafter, cells were incubated in the presence or absence
of increasing concentrations of RSV analogue PDM02 or
RSV at 100 lM for 1 h or 7 days in aMEM containing
10% FCS and 25 ng/mL rhM-CSF and then exposed to
100 ng/mL of rhRANKL for 30 min at 37C. Cells were
then fixed and stained with mouse monoclonal anti-p65
antibody as described [10]. Cells showing bright staining
for p65 in the nucleus were scored, and the results were
presented as the number of cells with NF-jB nuclear
translocation as a percentage of the total number of cells
counted.
Real-Rime Quantitative PCR on OB Cultures
For real-time PCR analysis of the expression of OB
markers, total RNA was isolated from cultured hMSC-
TERT cells using a single-step method with TRIzol
(Invitrogen, Taastrup, Denmark) according to the manu-
facturer’s instructions. The integrity and purity of isolated
RNA were verified by spectrophotometry and gel electro-
phoresis, and total RNA was then transcribed into cDNA
using RevertAid H Minus first-strand cDNA synthesis kit
(Fermentas, Copenhagen, Denmark) as recommended by
the manufacturer. Quantitative PCR and gene expression
analysis of the target gene and endogenous control b-actin
was done as described previously [36]. Expression levels
for each target gene and endogenous control were calcu-
lated using the comparative Ct method [(1/(2
DCt)] formula.
Animal Study
Sixty female virgin 8-month-old Sprague-Dawley rats
(Taconic, Lille Skensved, Denmark) were maintained
under standard conditions of 12-h day and night cycles.
Rats were housed two per cage and received common chow
and water ad libitum. Handling of the rats was in full
accordance with the European Community guidelines for
the care and management of laboratory animals.
Rats were randomized into six groups (n = 10/group), (1)
sham-operated (Sham), (2) OVX treated with estrogen
(OVX ? estrogen), (3) OVX treated with vehicle (OVX ?
DMSO), (4) untreated OVX, and OVX rats treated with (5)
high (40 mg/kg) or (6) low (4 mg/kg) dose of PDM02. At
surgery, 60-day slow-release pellets containing 0.05 mg
17a-ethylenestradiol (Innovative Research of America,
Sarasota, FL) were implanted subcutaneously in the
OVX ? estrogen group. For vehicle or PDM02 adminis-
tration, rats were deprived of food for 8 h, anesthetized with
4% isoflurane, and injected intraperitoneally every other day.
The body weight and health status of the animals were
monitored weekly. Blood samples (eye puncture) were
taken before surgery, twice during treatment (weeks 2 and
4), and at the end of the experiment (week 6, cardiac
puncture). Rats were killed by an overdose of pentobarbi-
tal, and the right and left tibiae were collected for further
analysis.
Volumetric BMD of tibiae was measured by peripheral
quantitative computed tomography (pQCT) using the XCT
Research M? pQCT machine (Stratec Medizintechnik,
Pforzheim, Germany). The voxel size was 0.100 mm. One
slice in the mid-diaphysis of the tibiae located 2 mm
proximal to the tibia-fibular junction and one slice in the
proximal tibial metaphysis located 2 mm distal from the
growth plate were measured. A threshold of 710 mg/cm3
was used for calculation of cortical BMD. For the mea-
surement of trabecular BMD in the proximal tibial
metaphysis, we used contour mode 1 and peel mode 20.
The percentage of trabecular bone was set to 50% of the
cross-sectional area.
Serum levels of CTX, a bone resorption marker, were
measured using Rat CrossLaps (IDS) as recommended by
the manufacturer.
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Statistical Analysis
Statistical comparisons were done with Student’s t-test or
one-way ANOVA followed by Dunnett’s post-test, and
P B 0.05 was considered significant (Prism v.5 program;
GraphPad, San Diego, CA). EC50 values were obtained
using nonlinear regression of the original data.
Results
Effect of RSV Analogues on Differentiating
and Mature OCs
Since RSV was previously shown to suppress RANKL-
mediated OC differentiation [10], we examined whether
RSV analogues have the same effect. We therefore cultured
CD14? monocytes in the presence of rhRANKL and
increasing concentrations of PDM02 for 7 days. When
compared with cultures treated with rhM-CSF alone,
rhRANKL induced the formation of numerous TRAP?
multinucleated cells (Fig. 1a, b), increased the levels of
TRAP activity in media (Fig. 1c), and strongly induced the
expression of cathepsin K (Fig. 1d), all known to be hall-
marks of OC differentiation. In contrast, simultaneous
treatment of differentiating cultures with PDM02 signifi-
cantly reduced the number of multinucleated cells staining
for TRAP, in a dose-dependent manner (Fig. 1b). More-
over, PDM02-treated cells showed changes in their mor-
phology, becoming spindle-shaped and resembling the
monocytic phenotype observed in wells treated only with
rhM-CSF (Fig. 1a) as did RSV-treated cells (Fig. 1a and
[10]). Also, the rhRANKL-induced TRAP activity in media
was diminished and the observed reduction was dose-
dependent (Fig. 1c). Similarly, the expression of cathepsin
K was strongly suppressed in cultures treated with PDM02
in a dose-dependent manner (Fig. 1d).
Similar experiments were performed for RSV and the
other four analogues listed in Table 1. Results of these
experiments are summarized in the table (Fig. 1e), and the
corresponding dose–response curves are shown in Sup-
plementary Figs. 1 and 2. In all experiments combined
treatment of OC precursors with rhM-CSF and rhRANKL
induced a mature OC phenotype. Supplementation of the
culture media with either PDM10 or PDM11 reduced the
levels of TRAP activity released into the culture media
(Supplementary Fig. 1) and suppressed the expression of
cathepsin K in a dose-dependent fashion. For PDM10, the
dose-dependent decrease of the number of TRAP? multi-
nucleated cells was also verified (Supplementary Fig. 2).
Neither PDM01 nor PDM06 showed any significant
inhibition of differentiating OCs (Online Resource 1 in
Supplementary material). Note that TRAP slightly
increased at the lower concentrations of PDM01, -02, and
-10 (not of PDM06 and -11); but this increase was not
significant. None of the analogues affected cell viability in
this OC differentiation model, as opposed to RSV, which
reduced the number of viable cells by 35% at 100 lM
(Fig. 1e). Thus, we conclude that PDM02, PDM10, and
PDM11 are strong inhibitors of OC differentiation, the
former two showing a 1,000-fold higher potency compared
to RSV.
Since the primary function of mature OCs is to resorb
bone, it was of interest to determine whether RSV ana-
logues could inhibit bone resorption in vitro. CD14? cells
were differentiated with rhM-CSF and rhRANKL as
described, and once they became mature OCs, they were
seeded on bone slices and exposed to increasing concen-
trations of PDM02. Figure 2 shows that rhRANKL induced
numerous pits yielding 8% of resorbed bone area. This
induction of pits was not affected by PDM02, and neither
was cell viability. Similar results were obtained for PDM10
(data not shown).
RSV Analogues Favor the Expression of Monocytic
Markers at the Expense of RANK during OC
Differentiation
As M-CSF/RANKL-induced osteoclastogenesis was
strongly inhibited in the presence of RSV analogues, we
tested their effect on the expression of RANK, which is
obligatory for inducing OC differentiation, and compared it
to the expression of broader myeloid markers. The expres-
sion of RANK was significantly reduced in the presence of
RSV analogues at the concentration range that inhibited OC
differentiation (100 nM to 1 lM) compared to cultures with
M-CSF/RANKL alone (Fig. 3). In contrast, c-fms gene
expression was significantly upregulated in the presence of
100 nM PDM02 or PDM10, a concentration that fully
inhibited OC differentiation, whereas at high dose (1 lM),
this effect was reversed (Fig. 3). On the other hand, PDM11,
exhibiting less potent inhibition of OC differentiation
(TRAP activity IC50 = 1.2 lM), induced higher expression
of the c-fms gene in the range 100 nM to 1 lM (Fig. 3).
Similarly to c-fms, expression of the lipopolysacharide
receptor CD14 was significantly upregulated by low doses
(10 and 100 nM) of RSV analogues PDM02 and PDM10,
whereas high doses (1 lM) suppressed CD14 expression.
Treatment with PDM11, with less potency toward differ-
entiating OCs, at concentrations ranging from 10 nM to
1 lM induced CD14 expression (Fig. 3). We conclude that
treatment with RSV analogues induces a similar expression
pattern of the monocytic markers c-fms and CD14, which is
clearly distinct from the effects on RANK expression. The
effects of RSV analogues on these markers parallel those
they have on OC generation from monocytes. When
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calculating these gene expressions relative to TRAP, the
same conclusions are reached (not shown).
RSV Analogues Act on NF-jB Activation
and on the NFATc1 Level
Stimulation of RANK during OC differentiation results in
NF-jB activation followed by induction of NFATc1
expression. We assessed the effect of RSV analogues on
NF-jB activation during OC differentiation by assaying
the nuclear translocation of its p65 component (Fig. 4).
As expected, transient stimulation with rhRANKL
increased the number of cells with p65 in the nucleus
compared to the cultures treated with rhM-CSF alone
(Fig. 4a). Pretreatment for 1 h or 7 days with PDM02
abrogated the rhRANKL-triggered translocation of p65 to
Fig. 1 Effect of RSV analogues on RANKL-induced OC differen-
tiation. Representative images of cell morphology at the end of 7-day
cultures after TRAP staining (a). Magnification 920. PDM02
treatment inhibits the formation of multinucleated TRAP? OCs
(b) and the level of TRAP activity (c). Each point represents the
mean ± SD of six cultures. * P \ 0.001, effect of PDM02 compared
with cultures in the presence of M-CSF (M) and RANKL (R) alone.
PDM02 inhibits expression of cathepsin K in differentiating OCs (d).
Bars represent means ± SD of three cultures. The table summarizes
experiments performed with RSV and other analogues (e). Cathepsin
K expressions are representative of at least two independent
experiments. The other results are representative of three independent
experiments involving six cultures each. nd not determined
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the nucleus and activation of NF-jB even at low doses
(Fig. 4a). Note for comparison that 1-h pretreatment with
RSV prior to adding rhRANKL was not sufficient to
prevent the nuclear translocation of NF-jB, whereas 7-
day treatment resulted in an inhibitory effect as previ-
ously reported [10].
As expected, rhRANKL increased the expression of
NFATc1 compared to control cells cultured with rhM-CSF
alone (Fig. 4b). Seven days of treatment with RSV,
PDM02, PDM10, or PDM11 at doses that were inhibitory
for OC differentiation significantly reduced NFATc1
expression. However, stimulatory activities were obtained
at lower doses of these RSV analogues (10 nM) at this
7-day time point, although not after 1-h treatment. At this
early time point, PDM10 and PDM11 already induced a
reduction in NFATc1, whereas RSV and PDM02 did
Fig. 2 Treatment with PDM02
has no effect on OC bone
resorption. Representative
images of bone slices exposed
to OCs treated with PDM02
(100 lM) or not (a).
Magnification 910. Resorbed
bone area was quantified and
expressed as a percentage of
total bone area (b). Each point
represents the mean ± SD of
six cultures
Fig. 3 Effect of RSV analogues
on the expression of myeloid
markers. Monocytes were
cultured for 7 days with M-CSF
with (filled square) or without
RANKL (filled square) in the
presence or absence of
increasing concentrations of
RSV analogues. Gene
expression determined by
Q-PCR was normalized to
human GUS and ABL, and the
relative expression is shown as a
percentage compared to control
cultures treated with M-CSF
and RANKL. Each point is the
mean ± SD of three cultures.
Results are representative of
two independent experiments.
* P \ 0.001
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not do so when used at the inhibitory doses for OC
differentiation.
PDM02 Promotes Osteoblast Differentiation
from hMSC-TERT Precursors
RSV was previously shown to induce the differentiation of
OBs from mesenchymal precursors [10]. Therefore, we
evaluated whether RSV analogues also possess osteogenic
potential. When culturing hMSC-TERT cells under osteo-
genic conditions in the presence of increasing concentra-
tions of PDM02 or 100 lM RSV, the expression of
osteogenic markers such as vitamin D3 receptor (VD3R),
osteocalcin, osteopontin (OPN), and alkaline phosphatase
(ALP) was upregulated relative to cells not treated with
PDM02 or RSV (Fig. 5). Levels of upregulation by
PDM02 were comparable to those induced by 100 lM
RSV at PDM02 doses of 10 nM for ALP, 5 lM for VD3R,
and 50 lM for osteocalcin. Although a twofold upregula-
tion of OPN was already detected at 0.5 lM PDM02,
higher doses did not cause further upregulation. In contrast,
eightfold upregulation was achieved by 100 lM RSV.
Treatment with PDM02 in the absence of osteogenic fac-
tors was inefficient to induce OB maturation (not shown),
Fig. 4 Effect of RSV and its
analogues on RANKL-mediated
NF-jB activation and NFATc1
expression in differentiating
OCs. One-hour or 7-day
treatment with PDM02
suppressed RANKL-induced
nuclear translocation of NF-jB
(a). Total numbers of cells
counted are given above in
parenthese for each condition.
Effect of PDM02, PDM10,
PDM11, and RSV (100 lM) on
NFATc1 gene expression in
differentiating OCs after 1 hour
or 7-day treatment with
analogues and RANKL (b).
Each bar is the mean ± SD
value relative to human GUS
and ABL of three cultures.
* P \ 0.05, ** P \ 0.01,
*** P \ 0.001 statistically
significant effect of PDM02
compared to cells cultured
without analogues. Results are
representative of two
independent experiments
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in contrast with RSV [10]. Cell numbers as evaluated
through metabolic activity were not affected by PDM02 in
these cultures. Similar experiments were performed for
PDM10 and PDM11 without reproducible results (not
shown).
RSV Analogues Do Not Show an Effect
on Proliferation and Survival of Myeloma Cells
RSV was previously shown to have a cytotoxic effect on
myeloma cells. Therefore, it was of interest to test RSV
analogues on myeloma cells. To this end, we treated
myeloma cell lines U266 and OPM-2 as well as primary
myeloma cells with all RSV analogues listed in Table 1 at
doses in the range of 1 nM to 100 lM in the presence or
absence of serum. Treatment with the RSV analogues did
not affect metabolic activity of these cells (data not
shown). No signs of apoptosis were observed in Annexin-
V-stained cells (data not shown). We concluded that these
RSV analogues have no effect on myeloma cell survival.
PDM02 Does Not Show a Significant Effect
on OVX-Induced Bone Loss
In vitro screening identified PDM02 as the most potent RSV
analogue of those listed in Table 1, strongly inhibiting OC
differentiation at a nanomolar concentration without non-
specific toxicity and promoting OB maturation. In order to
evaluate the in vivo relevance of these effects, we tested
PDM02 in OVX-induced osteoporosis in rats. To this end,
OVX animals were treated with either high (40 mg/kg) or
low (4 mg/kg) doses of PDM02 for 6 weeks. As expected,
OVX significantly reduced total BMD compared with sham-
operated animals, and this effect was partially prevented by
administration of estrogen (Fig. 6). Administration of vehi-
cle alone induced a further decline in BMD compared with
untreated OVX controls. PDM02 had no statistically sig-
nificant effect on BMD or bone area (whether total or tra-
becular) or CTX levels (whether at the 2- or 6-week time
point) in OVX rats (Fig. 6 and data not shown).
Discussion
RSV’s ability to simultaneously target the three critical cell
players in multiple myeloma–induced bone disease (OCs,
OBs, and myeloma cells) made it a very attractive potential
therapeutic agent with possible relevance to other bone
pathologies. However, its limited bioavailability by oral
administration [18, 19] and too broad spectrum of activities
and undesired side effects [2, 3, 20] stimulated a search for
analogues that had preserved the therapeutic effect but
were without the side effects of the natural product. Our
study identified two compounds, PDM02 and PDM10,
which are at least 1,000 times more potent in terms of
inhibition of OC differentiation compared to RSV. Since
OCs have a short half-life, it may be anticipated that
exposure to these RSV analogues will also result in strong
inhibition of bone resorption, even if in vitro these
Fig. 5 Effect of PDM02 on the differentiation of hMSC-TERT cells
into OBs. hMSC-TERT cells were differentiated into OBs with ODM
for 3 (a–c) or 5 (d) days in the presence or absence of PDM02 at
indicated concentrations (black bars) or 100 lM RSV (gray bars).
The expression of (a) vitamin D receptor (VDR), (b) osteocalcin,
(c) osteopontin, and (d) alkaline phosphatase (ALP) was quantified by
real-time PCR and is shown relative to the expression of b-actin. Each
bar is the mean ± SD of three independent experiments. * P \ 0.01,
** P \ 0.001 statistically significant effect of PDM02 compared to
cells cultured without PDM02. The results are representative of two
independent experiments, *** P \ 0.0001
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compounds proved to be without direct effect on the bone
resorption process itself. Furthermore, PDM02 stimulated
OB maturation at 100 times lower concentrations than
RSV. In contrast to RSV, these analogues were inactive
against myeloma cells, and PDM02 could not protect
against OVX-induced bone loss.
The strong effects of PDM02, PDM10, and, to a lesser
extent, PDM11 on OC differentiation were demonstrated in
three different ways: (1) by inhibition of the formation of
TRAP-positive multinucleated cells, (2) by inhibition of
the release of TRAP in the medium, and (3) by downreg-
ulation of the expression of cathepsin K, all widely rec-
ognized hallmarks of OC differentiation.
The mechanism mediating their effect is not merely
broad cytotoxicity since the most effective compound
PDM02 acted at a dose 5,000 lower than RSV without
affecting cell viability, as was the case for the active dose
of RSV. Another indication of lack of cytotoxicity is the
absence of a direct effect on OC resorptive activity, as
mentioned above.
An interesting feature of RSV analogues compared to
RSV is the lack of affinity to the ER. Several studies have
previously shown that estrogen could directly inhibit OC
differentiation [37]. Therefore, it was plausible that the
effects of RSV on OCs seen in the present and previous
study [10] were ER-mediated. The present study rules out
this hypothesis since it shows that RSV derivatives which
do not bind the ER still inhibit OC differentiation.
Interestingly, however, even if RSV analogues differ
from RSV by lower cytotoxicity and lack of ER binding
affinity, they share with RSV the ability to target the key
molecules controlling OC differentiation. Indeed, both
RSV and its analogues interfere with M-CSF/RANKL
signaling and inhibit activation of NF-jB and NFATc1.
Treatment with RSV [10] and RSV analogues induced the
expression of c-fms while downregulating the expression of
RANK, thus retaining the monocytic phenotype of OC
progenitors. In agreement with this, CD14 is upregulated
and the monocytic spindle-like morphology was observed
for PDM02-treated cells, two features which were also
observed in the presence of RSV [10]. NF-jB and NFATc1
function downstream of RANKL signaling and play an
essential role in the developmental stage from monocyte
precursors to mature OCs. We showed that short treatment
with RSV analogues (30 minutes after exposure to
RANKL), even at 10 nM, significantly diminished nuclear
translocation of NF-jB required for RANKL signaling. At
the culture time where control cells differentiate into OCs
and show high NFATc1 levels, the RSV analogues at
concentrations between 100 nM to 1 lM reduce both OC
differentiation and NFATc1 expression. Noteworthy, at the
same time point, a lower concentration (10 nM) of PDM02,
PDM10, and PDM11 stimulated NFATc1; and in the case
of the former 2 analogues, this stimulation correlated with
a trend toward increased OC differentiation. This correla-
tion did not hold true for PDM11, however, thereby
Fig. 6 PDM02 does not show a
significant effect in an
ovariectomy model of
osteoporosis. Rats were either
sham-operated (SHAM) or
ovariectomized (OVX) and left
untreated (–) or treated for
6 weeks with estrogen (E),
vehicle (V), or PDM02 at a dose
of 40 or 40 mg/kg. BMD and
total cross-sectional area at the
tibial metaphysis were
measured as described in
‘‘Materials and methods’’. Each
point represents sample
measurement in respective
populations (n = 10/group).
* P \ 0.01, *** P \ 0.0001
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showing that there is no general mechanism by which RSV
analogues at low concentration tend to stimulate OC dif-
ferentiation. Interestingly also, NFATc1 and NF-jB do not
show an identical inhibition pattern. This difference reflects
the fact that NFATc1 is regulated not only by NF-jB but
also by the c-Fos and the Ca/calcineurin pathway, as well
as by NFATc1-mediated activation of its own promoter
resulting in autoamplification [38]. NFATc1 is thus
downstream of several ‘‘signaling modules’’ and integrates
them, whereas NF-jB activity is known to rise and fall
rapidly, acting as an early immediate signal [39].
In relation to RSV analogues as AhR ligands, it is of
interest to mention that NFATc1 was reported to be acti-
vated upon the engagement of AhR in the breast cancer cell
line MCF-7 [40]. Furthermore, NF-jB is also triggered
when AhR is activated so that NF-jB acts as a common
transcriptional factor for both RANKL and AhR-mediated
signaling. Recent results suggested a competitive model of
RANKL/AhR activation [41]. The AhR ligand was shown
to directly inhibit NF-jB activation and thus osteoclasto-
genesis. This effect was reversed by high concentrations of
RANK and by RSV with antagonistic properties toward
AhR [41]. Although these observations stress a close rela-
tion between the AhR, which is known to be a target for
RSV analogues, and NF-jB/NFATc1, which is shown here
to respond to the RSV analogues, they do not allow a full
understanding of our data. Indeed, PDM02 and PDM11 are
AhR antagonists, while PDM10 is an agonist (Table 1); but
they all displayed the same inhibitory effect toward OC
differentiation, and furthermore, RSV always showed
inhibitory activity ([10] and present results), in contrast
with the situation of Voronov et al. [42], where it was tested
in the presence of AhR agonists and stimulated resorption.
A characteristic of the extensive bone loss observed in
osteoporotic and some cancer patients is that increased
bone resorption is not compensated by enhanced bone
formation [43]. Formation of new bone is mediated by OBs
that differentiate from mesenchymal stem cells in response
to different hormones or local factors. Previous studies
showed that RSV induced the mature phenotype in OB
precursors [11] while decreasing adipocyte formation from
mesenchymal precursors in favor of osteogenesis [44]. In
our study we demonstrated that only PDM02 was able to
promote the mature phenotype in hMSC-TERT. PDM02
induced the expression of VDR, OPN, osteocalcin, and
ALP as important characteristics of OB differentiation.
RSV analogues used in the study displayed different
binding affinities to AhR and acted either as antagonists or
as agonists.
The occupancy of AhR by dioxins has been correlated
with suppression of OB maturation [33]. This dioxin-
induced suppression could be reduced by simultaneous
treatment with RSV, acting strongly antagonistically on
AhR [12]. PDM02 is a 140 times more potent antagonist of
AhR than RSV and correspondingly affected OB differ-
entiation at lower concentrations compared to RSV.
However, treatment of MSC-TERT cells with PDM10 and
PDM11—respectively, an AhR agonist and antagonist—
did not give reproducible results. Therefore, the stimula-
tory properties of PDM02 on OBs cannot be clearly
interpreted as being mediated through AhR.
In multiple myeloma, cancer cells promote OC activa-
tion and induce bone resorption [45–47] while suppressing
bone formation. We previously demonstrated cytotoxic and
proapoptotic properties of RSV on myeloma cells [10] on a
molecular basis explained by inhibition of the constitu-
tional activation of NF-jB in myeloma cells [15]. In the
present study we tested several RSV analogues and none of
them showed antagonistic activity against either primary
myeloma cells or myeloma cell lines. This discrepancy
could be related to the fact that the tested analogues are
structurally modified and dihydroxyl groups in RSV were
replaced. Indeed, several recent studies with RSV and its
natural or synthetic analogues underscore the importance
of 3,4-dihydroxyl groups in exhibiting cytotoxic and
proapoptotic activities [48]. Furthermore, Murias and col-
leagues [24] clearly demonstrated that hydroxyl groups are
critical and that the natural RSV analogue piceatannol
containing four hydroxyl groups exhibited more cytotox-
icity toward leukemia cells than the trihydroxystilbene
RSV. Accordingly, compounds lacking hydroxyl groups
such as rhaponticin and stilbene performed poorer than
RSV and piceatannol, confirming the importance of
hydroxyl groups [23].
Among five analogues, only PDM02 both inhibited the
differentiation of OCs and induced OB maturation in a
nanomolar range, although it could not antagonize mye-
loma cells. Based on these observations, we tested the
efficacy of PDM02 in vivo, using OVX rats as a model of
human postmenopausal osteoporosis. It was reported that
low-dose RSV given by force-feeding for 12 weeks had a
beneficial effect on BMD and bone calcium content in
OVX rats [49], despite its low bioavailability. In our study,
the RSV analogue PDM02 administered intraperitoneally
for 6 weeks had no significant effect on the loss of BMD or
on serum CTX, which is a marker of bone resorption. The
differences between our results and those of Liu et al. [49]
may be due to the duration of the experiment (6 vs.
12 weeks), to the nature of the drug itself, or to different
drug-administration modes (intraperitroneal injection vs.
gavage). In our system, PDM02 was dissolved in DMSO,
and administration of DMSO alone induced further bone
loss compared with untreated OVX animals. It cannot be
ruled out that DMSO dosing provoked inflammation and
that the release of inflammatory cytokines caused further
bone loss [reviewed in 50]. Thus, the lack of bone-sparing
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effects of PDM02 in vivo could be a result of DMSO
administration. Regarding the drug itself, one may also
speculate that the lack of in vivo effect of PDM02 may be
due to low bioavailability. The bioavailability of PDM02 is
unknown. Injected PDM02 could be rapidly excreted from
the body, as is the case for RSV. A recent study suggested
that RSV is mainly absorbed in the small intestine as RSV
glucuronide [19]. Glucuronides of phenolic compounds are
thought to be rapidly excreted in vivo and to be pharma-
cologically inactive [51]. PDM02 could be processed in the
same or a similar way, thereby rapidly losing the activity
demonstrated in vitro or maybe falling in the low con-
centration range where a trend to higher TRAP and
NFATc1 was detected in culture conditions. Lack of effi-
cacy might also be explained by the fact that PDM02’s
inhibitory activity is restricted to OC differentiation,
whereas strong antiresorptives such as bisphosphonates and
denosumab not only inhibit OC differentiation but also
directly inhibit OC bone resorption.
To our knowledge, the present study is the first to show
that RSV analogues strongly inhibit OC differentiation and
may promote OB differentiation. Therefore, RSV ana-
logues may be of potential therapeutic interest. However,
further studies are required in order to define their phar-
macological characteristics and pharmacodynamics with
the aim to achieve in vivo efficacy.
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